Jordan Atkins, MD, is an Assistant Professor of Medicine in the Division of Hospital Medicine and works primarily on the bone marrow transplant service as a hospitalist. He has an interest in teaching and mentorship of students and residents on the oncology service and aids in recruitment of internal medicine resident candidates through the IM program as an interviewer. Dr. Atkins has contributed to multiple clinical research publications within the realm of oncology, which aids in the management of the complex medical problems of solid organ and leukemia patients. He serves on the hospitalist BMT/Oncology and the patient care operations committees, with a primary focus on patient throughput, triage and QI for oncology patients.
Education
- BS, Biology: Morehouse College, Atlanta, GA (2010)
- MPHS: Washington University School of Medicine, St. Louis, MO (2013)
- Medical Degree: Washington University School of Medicine, St. Louis, MO (2015)
- Residency, Internal Medicine: Barnes-Jewish Hospital, Washington University School of Medicine, St. Louis, MO (2018)
Board Certifications
- American Board of Internal Medicine
Clinical Interests
Hospital medicine, inpatient care
Publications
Atkins J, Fiala M, Wang-Gillam A, Wildes TM. Racial Disparities in the Outcomes of Patients with Stage IV Pancreatic Adenocarcinoma are Mediated by Chemotherapy Utilization. Pancreas. 2016 Aug. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Atkins J, Fowler SA, Tuuli M, James SA, Wildes TM. Efficacy of Bortezomib-Based Regimens with or Without an Immunomodulatory Agent in Older Adults with Multiple Myeloma: A Systematic Review and Meta-Analysis. Blood. 2013 Nov 15. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Atkins J, Appleton CM, Fisher CS, Gao F, Margenthaler JA. Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer? Journal of Oncology. 2013 Jan 14. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Atkins J, Mushawah FA, Appleton CM, Cyr AE, Gillanders WE, Aft RL, Eberlein TJ, Gao F, Margenthaler JA. Positive margin rates following breast-conserving surgery for stage I-III breast cancer: palpable versus nonpalpable tumors. J Surg Res. 2012 Sep;177(1):109-15. 2012 Apr 10. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Elmore L, Myckatyn TM, Gao F, Fisher CS, Atkins J, Martin-Dunlap TM, Margenthaler JA. Reconstruction Patterns in a Single Institution Cohort of Women Undergoing Mastectomy for Breast Cancer. Ann Surg Oncol. 2012 Aug 10. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of Recurrence and Perceived Survival Benefit are Primary Motivators for Choosing Mastectomy over Breast-Conservation Therapy Regardless of Age. Ann Surg Oncol. 2012 Jul 26. Department of Surgery, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Presentations
25th Anniversary American Society of Blood and Marrow Transplantation, Poster session. Efficacy of Desensitization Therapy for Donor-specific Anti-HLA Antibodies in Patients Undergoing Haploidentical Hematopoietic Cell Transplant. Atkins J, Slade M, DiPersio JF, Westervelt P, Vij R, Gao F, Zou J, Romee R., Salt Lake City, UT, USA. 2018.
1st prize, Medical Student Competition, Committee of Cancer Abstract Contest, Missouri Chapter of the American College of Surgeons, 45th Annual Professional Meeting, Lake Ozark, MO, USA. 2012.
7th Annual Academic Surgical Congress, Oral Abstract Presentation. Positive Margin Rates Following Breast-Conserving Surgery for Stage I-III Breast Cancer: Palpable Versus Non-Palpable Tumors? Atkins J, Mushawah FA, Cyr A, Aft RL, Gillanders WE, Eberlein TJ, Margenthaler JA; 48.4 – Clinical. 2012.
7th Annual Academic Surgical Congress, Oral Abstract Presentation. Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer? Atkins J, Cyr A, Appleton CM, Fisher CS, Margenthaler, JA; 48.4 – Clinical Trials and Outcomes 3 – Prognostic Factors & Surgical Predictors; ASC20120484; Las Vegas, NV, USA. 2012.
45th Annual Professional Meeting, Committee of Cancer Abstract Contest, Missouri Chapter of the American College of Surgeons. Which Imaging Modality Is Superior for Prediction of Response to Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer? Atkins J, Cyr A, Appleton CM, Fisher CS, Margenthaler JA., Lake Ozark, MO, USA. 2012.
5th Annual Research Training Symposium and Poster Session. Knockdown of DDX21 using RNA interference via lentiviral delivery in breast cancer cell lines implicates its potential nuclear activity through its negative impact on cell growth and survival. Atkins J, Zhang Y, Weber J.; St. Louis, MO, USA. 2010.